Protocol Ledger

NCT05924100 · Phase II · RECRUITING

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Interventional Phase II clinical trial protocol NCT05924100 sponsored by Associazione Qol-one in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-03 Enrollment: 22 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05924100
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)22 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05924100
Protocol FieldVerified Registry Value
NCT IdentifierNCT05924100
Consolidated Lead SponsorAssociazione Qol-one
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment22 participants (ESTIMATED)
Registered Start Date2022-11-03
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI